BlinatumomabNeurotoxicity syndrome following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1998卷 / 1期

关键词：

D O I：

10.1007/s40278-024-53965-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：121 / 121

相关论文

共 50 条

[1] SorafenibDRESS syndrome following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 420 - 420
[2] BrexpiprazolePisa Syndrome following off-label use: case report
[J]. Reactions Weekly, 2022, 1910 (1) : 118 - 118
[3] BupivacaineCompartment syndrome following an off-label use: case report
[J]. Reactions Weekly, 2017, 1644 (1) : 61 - 61
[4] ModafinilDRESS syndrome following off-label use: case report
[J]. Reactions Weekly, 2022, 1925 (1) : 322 - 322
[5] FruquintinibPneumothorax following off-label use
[J]. Reactions Weekly, 2024, 2009 (1) : 272 - 272
[6] EnasidenibHepatitis following off-label use
[J]. Reactions Weekly, 2024, 2011 (1) : 174 - 174
[7] IbrutinibAnaemia following off-label use
[J]. Reactions Weekly, 2024, 2007 (1) : 181 - 181
[8] VemurafenibFever following off-label use
[J]. Reactions Weekly, 2024, 1998 (1) : 462 - 462
[9] ErdafitinibRetinopathy following off-label use
[J]. Reactions Weekly, 2024, 2001 (1) : 141 - 141
[10] RituximabToxoinfectious syndrome and off-label use
[J]. Reactions Weekly, 2023, 1986 (1) : 388 - 388

← 1 2 3 4 5 →